Therapeutic approach to respiratory infections in lung transplantation

Carolina Clajus, Francesco Blasi, Tobias Welte, Mark Greer, Thomas Fuehner, Marco Mantero

Research output: Contribution to journalArticlepeer-review


Lung transplant recipients (LTRs) are at life-long risk for infections and disseminated diseases owing to their immunocompromised state. Besides organ failure and sepsis, infection can trigger acute and chronic graft rejection which increases mortality. Medical prophylaxis and treatment are based on comprehensive diagnostic work-up including previous history of infection and airway colonisation to reduce long-term complications and mortality. Common bacterial pathogens include Pseudomonas and Staphylococcus, whilst Aspergillus and Cytomegalovirus (CMV) are respectively the commonest fungal and viral pathogens. Clinical symptoms can be various in lung transplant recipients presenting an asymptomatic to severe progress. Regular control of infection parameters, daily lung function testing and lifelong follow-up in a specialist transplant centre are mandatory for early detection of bacterial, viral and fungal infections. After transplantation each patient receives intensive training with rules of conduct concerning preventive behaviour and to recognize early signs of post transplant complications. Early detection of infection and complications are important goals to reduce major complications after lung transplantation.

Original languageEnglish
Pages (from-to)149-154
Number of pages6
JournalPulmonary Pharmacology and Therapeutics
Publication statusPublished - Jun 1 2015


  • Antiinfective therapy
  • Lung transplantation
  • Prophylaxis
  • Respiratory tract infections

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)
  • Biochemistry, medical


Dive into the research topics of 'Therapeutic approach to respiratory infections in lung transplantation'. Together they form a unique fingerprint.

Cite this